290 related articles for article (PubMed ID: 34564992)
1. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Pang Y; Xu L; Xu X
J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sorafenib combined with transcatheter hepatic arterial chemoembolization in treating intermediate-advanced hepatocellular carcinoma.
Kuang J; Wan D; Wan P; Wu D
J BUON; 2021; 26(3):868-874. PubMed ID: 34268947
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang M; Yuan JQ; Bai M; Han GH
Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.
Cao DD; Xu HL; Liu L; Zheng YF; Gao SF; Xu XM; Ge W
Oncotarget; 2017 Jul; 8(27):44976-44993. PubMed ID: 28402958
[TBL] [Abstract][Full Text] [Related]
5. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
[TBL] [Abstract][Full Text] [Related]
6. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Cai R; Song R; Pang P; Yan Y; Liao Y; Zhou C; Wang S; Zhou X; Wang H; Zhang H; Sun H; Ma H
BMC Cancer; 2017 Nov; 17(1):714. PubMed ID: 29110700
[TBL] [Abstract][Full Text] [Related]
7. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
Xie Y; Tian H; Xiang H
Tumori; 2021 Aug; 107(4):292-303. PubMed ID: 32729385
[TBL] [Abstract][Full Text] [Related]
8. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
Hepatol Int; 2016 May; 10(3):501-10. PubMed ID: 26856326
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
12. Sorafenib combined with transarterial chemoembolization prolongs survival of patients with advanced hepatocellular carcinoma.
Liu Q; Dai Y
J BUON; 2020; 25(2):945-951. PubMed ID: 32521890
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
Liu L; Chen H; Wang M; Zhao Y; Cai G; Qi X; Han G
PLoS One; 2014; 9(3):e91124. PubMed ID: 24651044
[TBL] [Abstract][Full Text] [Related]
15. Trans-catheter arterial chemoembolization plus Sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma?: A systematic review and meta-analysis.
Zhang T; Huang W; Dong H; Chen Y
Medicine (Baltimore); 2020 Jul; 99(29):e20962. PubMed ID: 32702836
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
Xie Y; Tian H; Xiang B; Zhang Y; Liu J; Cai Z; Xiang H
Medicine (Baltimore); 2021 Aug; 100(33):e26958. PubMed ID: 34414963
[TBL] [Abstract][Full Text] [Related]
18. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
[TBL] [Abstract][Full Text] [Related]
19. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
20. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
